The Drug Enforcement Administration has opened a new federal registration pathway for state-licensed medical marijuana manufacturers, distributors and analytical laboratories, marking another major step in the government’s implementation of Schedule III rules for medical cannabis. The DEA’s Diversion Control Division activated the new application process on October 5, 2026, allowing qualifying cannabis businesses to use DEA Form 225 to seek federal controlled-substance registrations covering activities such as cultivation, processing, distribution and laboratory analysis.
The move expands a federal registration framework that began earlier this year after the Department of Justice placed marijuana products covered by state medical marijuana licenses, along with FDA-approved marijuana medicines, into Schedule III of the Controlled Substances Act. Medical marijuana dispensaries received their own federal registration pathway first. Manufacturers, distributors and testing laboratories can now formally enter the system as well, potentially creating a federally recognized medical cannabis supply chain that operates alongside existing state programs. Recreational marijuana remains outside that framework and continues to be treated differently under federal law.
DEA Form 225 Now Covers Medical Cannabis Businesses
The new registration process uses DEA Form 225, the same general application used for controlled-substance manufacturers, distributors, researchers, analytical laboratories, importers and exporters. Medical marijuana applicants are asked to identify their business activity, confirm the controlled-substance schedule involved and provide information about their state license. The application specifically asks whether the business intends to handle medical marijuana, recreational marijuana or both, reflecting the continuing federal distinction between the two markets.
Applicants can identify marijuana, marijuana extract and naturally derived delta-9 THC contained in an FDA-approved product or marijuana covered by a state medical marijuana license as substances they intend to handle. Manufacturers may also have to describe whether they cultivate cannabis, extract cannabinoids, process products or repackage them. The DEA’s current registration fees are $3,699 per year for manufacturers, $1,850 for distributors and $296 for analytical laboratories conducting chemical analysis. Businesses that already submitted applications during the earlier implementation period have been told they do not need to submit a second application.
Manufacturers Can Cultivate, Process and Transfer Medical Marijuana
Under the new federal rules, a registered medical marijuana manufacturer may cultivate, produce, process, package, label and transfer marijuana or marijuana products within the limits of its state medical cannabis license. Transfers can be made to other federally registered manufacturers or registered distributors. The structure is designed to recognize the cultivation and processing systems already operating in state medical marijuana programs rather than forcing states to rebuild their industries around an entirely separate federal production model.
The federal registration does not give a company broader authority than it already holds under state law. A cultivator cannot use DEA registration to conduct activities prohibited by its state license, and federal registration is automatically affected if the underlying state license is suspended, revoked or expires. The Department of Justice said when establishing the system that state medical marijuana programs have developed sufficiently mature inspection, inventory, security and diversion-control systems to serve as the foundation of the federal framework. That represents a major shift from decades in which state marijuana businesses generally operated without direct federal recognition.
Distributors Become Part of a Federally Registered Supply Chain
Federally registered distributors may receive medical marijuana and marijuana products from registered manufacturers and transfer those products to registered dispensaries or other registered distributors, again subject to state licensing restrictions. In practical terms, the rule creates the legal architecture for a medical cannabis supply chain in which cultivation, production, wholesale movement and retail dispensing can each occur through businesses holding both state authorization and federal DEA registration.
This structure could become particularly important in states where cannabis businesses are not required to operate as fully vertically integrated companies. A cultivator may produce flower, another business may manufacture extracts or finished products, a distributor may transport inventory and a separate dispensary may sell it to qualifying patients. Before the Schedule III medical framework, those transactions remained fundamentally inconsistent with federal controlled-substance law even when every participant complied with state regulations. DEA registration does not eliminate every federal restriction, but it gives qualifying medical operations a route into the federal controlled-substance system.
Testing Laboratories Could Become Increasingly Important
The opening for analytical laboratories may have some of the most important long-term scientific consequences. State cannabis markets depend heavily on laboratories to measure THC, CBD and other cannabinoids while also screening products for contaminants such as pesticides, heavy metals, residual solvents, microbes and mycotoxins. Yet marijuana’s longstanding federal Schedule I treatment has complicated the relationship between commercial testing laboratories, academic researchers and federal controlled-substance regulations.
Recent research illustrates why laboratory oversight matters. A 2024 study examining 107 cannabis flower products purchased from dispensaries in Colorado, Oregon and California found that only about 30 percent had measured THC concentrations within 20 percent of their label claims. A later Colorado study analyzing 277 flower and concentrate products also found systematic discrepancies between labeled and independently measured THC concentrations, with flower products showing substantially more variability than concentrates. These findings do not mean every licensed laboratory produces inaccurate results, but they demonstrate why independent analytical capacity and standardized testing methods are central to both consumer protection and credible medical research.
Federal Registration Could Help Researchers Study Real-World Cannabis
One of the longstanding problems in American marijuana research has been the difference between cannabis available to scientists and cannabis actually used by patients. For decades, federally authorized researchers had access to a limited supply of government-produced marijuana that often differed considerably in potency, chemical diversity and product form from material sold in state dispensaries. Researchers repeatedly warned that studying low-potency federal cannabis might not accurately predict the effects of commercially available flower, concentrates, oils or other preparations.
A 2017 analysis comparing federally produced cannabis with products available in legal state markets found significant differences in cannabinoid profiles. The researchers reported that federal research cannabis contained considerably lower THC concentrations and less chemical diversity than products consumers could buy through state-regulated dispensaries. The National Academies of Sciences, Engineering, and Medicine reached a similar conclusion in its major review of cannabis research, identifying access to appropriate cannabis products as an important barrier to high-quality research. Expanding the number of federally registered manufacturers and laboratories could gradually narrow that gap by giving researchers access to products that more closely resemble what medical marijuana patients actually use.
Researchers Have Long Identified DEA Rules as a Major Barrier
The difficulty of obtaining and studying cannabis has been documented repeatedly in scientific literature. A 2021 review involving researchers from the National Institutes of Health, FDA and academic institutions identified three major obstacles to clinical cannabis research: federal regulatory requirements, difficulty obtaining appropriate cannabis products and inadequate research funding. Scientists frequently had to navigate DEA registration, FDA requirements, institutional review boards, state regulations and special storage rules before a study could even begin.
Research published following passage of the Medical Marijuana and Cannabidiol Research Expansion Act described similar difficulties. Investigators reported delays obtaining appropriate study products, limited varieties of federally available cannabis and administrative processes that could add months to study timelines. While DEA reforms over the past several years have gradually expanded federally registered cannabis manufacturers and simplified some research requirements, the new Schedule III medical registration system could represent a broader structural change by bringing commercial state-licensed companies closer to the federally regulated research environment.
The Federal Rule Specifically Protects Certain Research Transfers
The April 2026 federal rule contains an important provision for researchers obtaining marijuana from federally registered state licensees. A researcher who is properly registered with DEA to conduct marijuana research will not face Controlled Substances Act liability solely because the cannabis originated from a state-licensed medical marijuana company rather than a traditional federal bulk manufacturer, provided the supplying company held a valid DEA registration at the time of the transfer.
That language could significantly expand the range of products available for scientific investigation. Researchers may eventually be able to examine specific commercial-style formulations, cannabinoid ratios, delivery methods and potency ranges that better reflect patient use. This could be particularly valuable for research involving chronic pain, epilepsy, multiple sclerosis symptoms, sleep disorders, anxiety, chemotherapy-related symptoms and other conditions for which patients already use state-authorized medical cannabis. Better product access does not guarantee positive clinical findings, but it can make studies more representative of real-world treatment.
State Regulations Will Continue Doing Much of the Day-to-Day Work
One of the more unusual aspects of the new federal model is the extent to which DEA is relying on state cannabis regulations. The federal rule says state-required records, reporting systems and forms should be accepted to the greatest extent permitted under federal law. State-compliant security systems can also satisfy federal physical-security requirements for registered medical marijuana businesses, and state labeling, packaging and disposal standards can generally continue to govern qualifying products.
This approach is intended to prevent companies from having to operate under two completely different regulatory systems. State cannabis agencies already monitor inventory, conduct inspections, license facilities and impose rules governing product movement and security. Rather than duplicating every requirement, DEA is effectively layering federal registration over existing medical cannabis structures. The agency still retains authority to deny, suspend or revoke registration when federal public-interest concerns arise, and international treaty obligations remain part of its review.
International Treaty Rules Still Influence Marijuana Manufacturing
The federal framework also contains provisions designed to satisfy the United States’ obligations under the 1961 Single Convention on Narcotic Drugs. The treaty requires government control over certain aspects of cannabis production. To meet those requirements without physically routing every crop through a federal warehouse, DEA established a nominal purchase-and-resale system for federally registered marijuana manufacturers.
Manufacturers must establish a nominal price for their marijuana crops. DEA then legally purchases the cannabis at that price and sells it back to the manufacturer or a related entity, adding an administrative fee. For 2026, that fee is calculated on a per-kilogram basis. Manufacturers must also store marijuana in facilities accessible to DEA until the required transaction is completed, and federal registrations identify the areas where cultivation is permitted. The process is largely administrative, but it illustrates how international drug-control treaties continue shaping federal cannabis policy even as domestic marijuana laws become more permissive.
Recreational Marijuana Is Not Covered by the New System
The most important limitation is that federal registration under the medical marijuana rules does not authorize recreational cannabis activity. Marijuana manufactured, distributed or sold outside an FDA-approved drug product or qualifying state medical marijuana program generally remains outside the Schedule III medical framework. A company participating in both medical and adult-use markets therefore faces a complicated situation in which one portion of its business may receive federal recognition while another continues operating under a different federal classification.
DEA’s application itself highlights that distinction by asking applicants whether they intend to handle medical or recreational marijuana. Federal registration for medical activity does not transform adult-use inventory into Schedule III material or authorize interstate recreational commerce. Businesses with mixed operations may consequently need detailed inventory controls and accounting systems capable of identifying which products and transactions belong to the federally recognized medical side of the company.
Schedule III Could Have Major Financial Consequences
Federal registration is also closely connected to one of the cannabis industry’s largest financial issues: Internal Revenue Code Section 280E. That provision blocks ordinary business deductions for companies trafficking in Schedule I or Schedule II controlled substances. Because Schedule III substances are not covered, qualifying medical cannabis businesses could potentially deduct expenses such as payroll, rent, insurance and other ordinary operating costs once their activities fall within the Schedule III framework.
The Department of Justice stated in its April rule that holders of qualifying state medical marijuana licenses would no longer be subject to Section 280E for covered activity, although federal tax authorities are still developing guidance explaining how the change applies in practice. Questions remain especially complicated for companies serving both medical patients and recreational consumers. The new DEA registration process could nevertheless become an important piece of establishing which operations are participating in the federally recognized Schedule III medical market.
A Major Shift From Prohibition Toward Federal Oversight
The opening of DEA Form 225 registration for medical marijuana manufacturers, distributors and analytical laboratories does not amount to federal marijuana legalization. Cannabis remains heavily controlled, recreational marijuana remains outside the new medical framework and companies must continue complying with state licensing requirements. What has changed is the federal government’s approach to state medical marijuana businesses. Instead of treating the entire state-regulated supply chain as activity occurring outside federal controlled-substance law, DEA is now building a registration system designed to bring qualifying operators inside it.
The development could ultimately be as important for science as it is for business. Researchers have spent years warning that federal restrictions prevented them from studying marijuana products that accurately represented modern cannabis markets. Peer-reviewed studies have documented discrepancies in product labeling, major differences between federal research cannabis and commercial products and persistent regulatory obstacles to clinical research. Bringing cultivators, processors, distributors and testing laboratories into a federal registration structure could create a more realistic environment for studying medical cannabis while establishing stronger links between state regulation, federal oversight and scientific testing. Whether the new system works smoothly will depend on how quickly DEA processes applications and how businesses adapt to the additional requirements, but the October 2026 portal marks another significant transition in the federal government’s treatment of medical marijuana.
